Regulatory Filings • Apr 17, 2012
Regulatory Filings
Open in ViewerOpens in native device viewer
Unilab Group, based in the Philippines, is a leading pharmaceutical and healthcare company in South East Asia. In Taiwan a distributor called Avipha Biotechnology Co., Ltd, will sell the products, which will be marketed under BioGaia's own brand. Both products contain BioGaia's patented and wellresearched probiotic strain Lactobacillus reuteri Protectis. Today the drops are available in 51 countries worldwide and the tablets in 46.
BioGaia already has an agreement with Unilab Group for distribution of the tablets in the Philippines, and with Unilab's subsidiary in China, SUCB, for the drops.
– We are pleased with the agreement with Unilab/Avipha. As Taiwan has a population of 23 million people and the standard of living is among the top 20 countries of the world, the potential for our probiotic products should be good, says Peter Rothschild, President, BioGaia.
Peter Rothschild, President, telephone: +46 8 555 293 00
| 2012-04-04 | Notice to attend the annual general meeting of BioGaia AB (publ) |
|---|---|
| 2012-03-21 | The Board of BioGaia proposes that the AGE approve an extraordinary dividend… |
| 2012-02-22 | Lactobacillus reuteri Protectis reduced diarrhoea in children |
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 17 April 2012, 10:30 am CET.
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.